BCL2 and malignant colon neoplasm: Recent studies have demonstrated that combination treatment with MDM2 inhibitor and Bcl-2 inhibitor results in synergistic anti-tumor activity compared with the respective single-agent treatments in acute myeloid leukemia and colon cancer cells [52, 53].